Zura Bio Limited (NASDAQ:ZURA) Receives $16.75 Average Price Target from Analysts

Shares of Zura Bio Limited (NASDAQ:ZURA) have been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $15.80.

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. Leerink Partnrs upgraded shares of Zura Bio to a “strong-buy” rating in a research note on Monday, November 4th. Chardan Capital dropped their price target on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Leerink Partners initiated coverage on shares of Zura Bio in a research note on Monday, November 4th. They set an “outperform” rating and a $15.00 price target on the stock.

Zura Bio Trading Up 3.1 %

ZURA stock opened at $4.72 on Tuesday. Zura Bio has a 12-month low of $2.00 and a 12-month high of $6.35. The company has a 50 day moving average of $4.19 and a two-hundred day moving average of $4.12.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Equities research analysts expect that Zura Bio will post -0.49 EPS for the current fiscal year.

Insider Activity at Zura Bio

In related news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total value of $200,187.36. Following the transaction, the director now directly owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 22.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Great Point Partners LLC grew its stake in Zura Bio by 68.3% in the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after buying an additional 1,884,501 shares during the last quarter. Armistice Capital LLC grew its position in Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after purchasing an additional 876,000 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Zura Bio in the 2nd quarter worth $8,446,000. Affinity Asset Advisors LLC acquired a new stake in Zura Bio in the 1st quarter worth $1,157,000. Finally, Bank of New York Mellon Corp grew its position in Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock worth $165,000 after purchasing an additional 6,412 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.